Sobi’s Orfadin® oral suspension granted European patent

A drug named Orfadin® (nitisinone) an oral suspension formulation for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) has been granted a patent by the EPO. Hereditary Tyrosinaemia type-1 (HT-1) is a rare genetic disease affecting children. [More]